ZDHHC20

Across TCGA pan-cancer cohorts, ZDHHC20 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of ZDHHC20’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ZDHHC20 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ZDHHC20 is over-expressed in tumor, although a few such as KICH and LUSC show the opposite, repressed pattern.

KIRC, BLCA, and KICH are the cancer types where ZDHHC20 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZDHHC20 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+0.671	<.001	11	view →
BLCA	All	III,IV	+0.911	.001	8	view →
KICH	Female	II,III,IV	−1.300	<.001	7	view →
PAAD	All	All	+1.060	<.001	6	view →
BRCA	All	II,III,IV	+0.591	<.001	6	view →
LIHC	All	All	+0.394	.006	5	view →
CHOL	All	All	+1.324	.006	4	view →
UCEC	All	III,IV	+0.835	.033	4	view →
COAD	Male	II,III,IV	+0.762	<.001	4	view →
STAD	All	All	+0.506	.014	4	view →
READ	All	II,III,IV	+0.714	.027	3	view →
ESCA	All	All	+0.956	.015	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

ZDHHC20–KIRC

Open the KIRC breakdown →